|1.||Hart, Robert G: 5 articles (04/2007 - 10/2002)|
|2.||Lip, Gregory Y H: 4 articles (02/2014 - 10/2002)|
|3.||Weiss, Norbert: 2 articles (06/2015 - 04/2015)|
|4.||Gelbricht, Vera: 2 articles (06/2015 - 04/2015)|
|5.||Beyer-Westendorf, Jan: 2 articles (06/2015 - 04/2015)|
|6.||Michalski, Franziska: 2 articles (06/2015 - 04/2015)|
|7.||Sahin, Kurtulus: 2 articles (06/2015 - 04/2015)|
|8.||Tittl, Luise: 2 articles (06/2015 - 04/2015)|
|9.||Endig, Heike: 2 articles (06/2015 - 04/2015)|
|10.||Ebertz, Franziska: 2 articles (06/2015 - 04/2015)|
03/01/2014 - "Among those who had CHADS2 scores of 0, 64 patients (97.0%) were receiving appropriate stroke prevention in AF (SPAF) treatment according to the 2010 guidelines. "
09/01/2007 - "As indicated by c statistics and hazard ratios, 3 of the classification schemes predicted stroke significantly better than chance: Framingham (c=0.64), CHADS(2) (c=0.65), and SPAF (c=0.61). "
07/01/2007 - "Framingham equations gave lower stroke risks overall than SIGN or SPAF. "
09/01/2005 - "The proportions of patients stratified as having high/moderate/low risk of stroke according to each CCS were: 70%/22%/8% (AFI), 38%/41%/21% (SPAF), 13%/45%/42% (CHADS(2)), and 86%/7%/7% (ACCP). "
05/20/2003 - "The SPAF III stroke risk stratification scheme has been validated for identifying patients with high versus moderate versus low risk for stroke. "
11/01/1998 - "Aortic atherothrombosis was also recently associated with increased cardiovascular complications in patients with atrial fibrillation (SPAF III trial)."
10/10/1998 - "According to analyses derived from risk stratifications based on the Stroke Prevention in Atrial Fibrillation (SPAF) study 61% of these patients would have benefited from anticoagulation, 49% according to pooled analysis of trial results, and 41% according to the inclusion criteria for the SPAF 3 study. "
01/26/2005 - "Our retrospective analysis of prospectively collected data examined the antithrombotic therapy of patients with first-ever stroke and known non-valvular AF and compared the results with the recommendations of the Atrial Fibrillation Investigators (AFI) and the Stroke Prevention in Atrial Fibrillation (SPAF) study. "
01/01/2004 - "The optimum use of anticoagulation to reduce stroke risk has been explored by the Stroke in Patients with Atrial Fibrillation (SPAF) studies. "
12/01/1999 - "We analyzed transesophageal echocardiograms from 772 participants in the Stroke Prevention in Atrial Fibrillation (SPAF-III) study, characterizing spontaneous echocardiographic contrast (SEC) in the left atrium or appendage as faint or dense. "
08/09/2012 - "Patients were classified as at low, moderate, or high risk of thromboembolism based on seven clinical risk stratification schemes (SPAF, CHADS(2), Framingham, Birmingham/NICE, ACC/AHA/ESC 2006 guidelines, ACCP 2008, CHA(2)DS(2)VASc). "
09/01/2006 - "We classified 994 AF patients who were enrolled in the SPAF III trial as being at low, moderate, or high risk of stroke and thromboembolism according to the Birmingham and CHADS(2) risk stratification schemes. "
05/01/2003 - "Stroke Prevention Atrial Fibrillation (SPAF) III study showed washing flow, left appendage ejection fraction, natural echocontrast, and left appendage volume and morphology, as risk parameters of thromboembolism. "
12/01/1999 - "Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)."
12/01/1999 - "Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)."
10/01/1994 - "In patients with congestive heart failure on antiarrhythmic therapy, the SPAF trial has shown an increase in cardiac mortality and arrhythmic deaths. "
07/01/2007 - "Stroke risk was compared in 193 patients with atrial fibrillation using the Framingham equation; an atrial fibrillation-specific Framingham equation; the Congestive heart failure, Hypertension, Age, Diabetes and Stroke (CHADS(2)) score; the Stroke Prevention and Atrial Fibrillation (SPAF) scheme; and the Scottish Intercollegiate Guidelines Network (SIGN) guidelines. "
09/01/2005 - "The proportions of patients classified as having high, moderate, and low risk of stroke among the following CCSs were compared: the Atrial Fibrillation Investigators (AFI), the Stroke Prevention in Atrial Fibrillation (SPAF), the CHADS(2) (an acronym for congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack), and the American College of Chest Physicians (ACCP). "
06/01/2005 - "To examine further the relations of plasma von Willebrand factor (vWf, an index of endothelial damage and dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations to the presence and onset of clinical congestive heart failure (CHF) and the degree of left ventricular (LV) dysfunction in patients taking part in the SPAF (stroke prevention in atrial fibrillation) study. "
01/01/2001 - "Anticoagulation with warfarin using international normalised ratios (INRs) ranging from 2.0 to 3.0 is recommended for patients with NVAF, who have any of the risk factors identified by the Atrial Fibrillation Investigators (AFI) [previous stroke or TIA, history of hypertension, diabetes mellitus, advanced age (> or = 65 years old), congestive heart failure and coronary artery disease], the American College of Chest Physicians (ACCP) [increased age (> 75 years old), prior stroke, hypertension and heart failure], or the Stroke Prevention in Atrial Fibrillation (SPAF) investigators [women > 75 years old, prior stroke, systolic blood pressure > 160mm Hg, recent heart failure, and fractional shortening < 25% on echocardiography]. "
09/01/1994 - "Conscious of the importance of the risk of embolism in AF, several authors have undertaken, over the last few years, randomised studies of the prevention of thromboembolic complications of AF: the AFASAK, BAATAF, SPAF and SPINAF trials. "
01/01/2001 - "SPAF III (INR 2.0 to 3.0) demonstrated a lower incidence of ischaemic stroke or systemic embolism (3.4 %/year) compared with low fixed-dose warfarin plus aspirin (acetylsalicylic acid) [11.9%]. "
11/01/1990 - "The Stroke Prevention in Atrial Fibrillation Study recently found and reported (SPAF Investigators, N Engl J Med, 1990;322:863-868) a beneficial effect of both warfarin and aspirin compared with placebo in the primary prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. "
|1.||Aspirin (Acetylsalicylic Acid)
|4.||von Willebrand Factor
|5.||Apoprotein(a) (Apolipoprotein (a))
|10.||Protein Kinase C
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)